Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma

By P. Meliante, Federica Zoccali, M. de Vincentiis, M. Ralli, C. Petrella, M. Fiore, A. Minni, C. Barbato. 2023

Subfields: Immunology and Allergy, Oncology, Otorhinolaryngology

Citations in the corpus

• Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “The introduction of the anti-PD-1 antibodies Pembrolizumab and Nivolumab raised hopes for better overall survival in patients with recurrent or metastatic tumors, but response rates to immune checkpoint therapy remain poor, with only 20–30% of patients experiencing long-term benefit [7].”